Global COVID-19 cases have surpassed 775 million. The pandemic's legacy includes shifting transmission patterns, evolving vaccine protection, and a lasting economic and health burden.
Key Takeaways
- 775,000,000+ confirmed COVID-19 cases worldwide (cumulative, as of May 2026: June 2026).
- 7,000,000+ confirmed COVID-19 deaths worldwide (cumulative, as of May 2026: June 2026).
- The CDC reported that the proportion of COVID-19 cases caused by Omicron increased from about 0% to over 95% in the US between December 2021 and February 2022.
- In a 2021 study, the estimated basic reproduction number (R0) for the original SARS-CoV-2 strain was around 2.5 (range 2–3).
- A 2022 NEJM article estimated that Omicron BA.1 was 7.8 times more transmissible than Delta in household settings.
- 74% of people aged 65+ in the United Kingdom had received a COVID-19 vaccine by March 2024 (cumulative coverage).
- 9.2% of the global population was fully vaccinated by 31 Dec 2021
- In a 2023 systematic review, vaccine effectiveness against death remained measurably higher for longer than against infection in multiple study designs.
- In a 2022 meta-analysis, adjusted vaccine effectiveness against hospitalization after booster dose ranged from about 80% at 2–4 weeks to about 50% by 10–14 weeks.
- In a 2022 Canadian test-negative study, 3 doses of mRNA vaccine were associated with 81% (95% CI 75–86) effectiveness against hospitalization during the period studied.
- COVID-19 reduced global GDP by about 3.1% in 2020 (World Bank estimate).
- In 2020, the International Monetary Fund estimated global real GDP contracted by 3.1% due largely to the pandemic (IMF World Economic Outlook).
- In 2020, the U.S. federal government obligated $5.2 trillion for COVID-19 response (Coronavirus Aid, Relief, and Economic Security and subsequent legislation).
- In 2020, 51% of employees in a Microsoft Work Trend Index survey reported working differently due to COVID-19 (remote/hybrid).
- In 2021, 41% of survey respondents globally reported they reduced in-person social activities due to COVID-19 (YouGov).
By May 2026, COVID-19 had reached over 775 million cases worldwide, with vaccines and public measures still key.
Related reading
01 · Category
Global Burden2 stats
01
775,000,000+ confirmed COVID-19 cases worldwide (cumulative, as of May 2026).
02
7,000,000+ confirmed COVID-19 deaths worldwide (cumulative, as of May 2026).
Interpretation
Global Burden Interpretation
From a global burden perspective, the pandemic has already surpassed 775,000,000 confirmed cases and 7,000,000 deaths worldwide by May 2026, showing the immense scale of lasting worldwide impact.
02 · Category
Variant & Transmission7 stats
01
The CDC reported that the proportion of COVID-19 cases caused by Omicron increased from about 0% to over 95% in the US between December 2021 and February 2022.
02
In a 2021 study, the estimated basic reproduction number (R0) for the original SARS-CoV-2 strain was around 2.5 (range 2–3).
03
A 2022 NEJM article estimated that Omicron BA.1 was 7.8 times more transmissible than Delta in household settings.
04
A 2020 preprint later widely cited estimated the incubation period median at about 5 days for SARS-CoV-2.
05
Ventilation and exposure duration matter: a 2021 study found that improving ventilation can reduce transmission risk by up to 70% under certain conditions.
06
A 2021 systematic review estimated that face masks reduce transmission of respiratory viruses by about 53% (including SARS-CoV-2 evidence where available).
07
A 2022 CDC analysis reported that NPI indicators (school closures, mobility reductions) were associated with lower transmission during earlier waves; median effect size corresponded to a 20–40% reduction in growth rate in modeled results.
Interpretation
Variant & Transmission Interpretation
Across key variants and transmission factors, COVID-19 spread shifted dramatically as Omicron rose to over 95% of US cases and was about 7.8 times more transmissible than Delta in households, while transmission risk was also cut roughly 53% with face masks and up to 70% with better ventilation.
03 · Category
Vaccination Coverage2 stats
01
74% of people aged 65+ in the United Kingdom had received a COVID-19 vaccine by March 2024 (cumulative coverage).
02
9.2% of the global population was fully vaccinated by 31 Dec 2021
Interpretation
Vaccination Coverage Interpretation
Vaccination coverage shows a clear gap in scale, with the UK reaching 74% cumulative coverage among those aged 65 and over by March 2024 while globally only 9.2% of people were fully vaccinated as of 31 December 2021.
04 · Category
Vaccine Effectiveness7 stats
01
In a 2023 systematic review, vaccine effectiveness against death remained measurably higher for longer than against infection in multiple study designs.
02
In a 2022 meta-analysis, adjusted vaccine effectiveness against hospitalization after booster dose ranged from about 80% at 2–4 weeks to about 50% by 10–14 weeks.
03
In a 2022 Canadian test-negative study, 3 doses of mRNA vaccine were associated with 81% (95% CI 75–86) effectiveness against hospitalization during the period studied.
04
In a 2021 study, Pfizer-BioNTech vaccine effectiveness against symptomatic SARS‑CoV‑2 infection was estimated at 88% (95% CI 82–92) shortly after dose 2.
05
In a 2021 study, Moderna vaccine effectiveness against symptomatic infection was estimated at 93% (95% CI 88–95) shortly after dose 2.
06
A 2022 observational study estimated that bivalent (updated) booster effectiveness against hospitalization was 74% (95% CI 58–83) compared with no booster during the period studied.
07
In a 2022 study, protection against severe disease after vaccination remained higher than protection against infection, with effectiveness declining over time.
Interpretation
Vaccine Effectiveness Interpretation
Across studies, vaccine effectiveness for severe outcomes stays stronger and longer than protection against infection, with booster or booster dose effectiveness against hospitalization commonly around 74% to 81% (and up to about 80% shortly after boosters), and effectiveness against death persisting measurably longer than effectiveness against infection.
05 · Category
Economic Impacts7 stats
01
COVID-19 reduced global GDP by about 3.1% in 2020 (World Bank estimate).
02
In 2020, the International Monetary Fund estimated global real GDP contracted by 3.1% due largely to the pandemic (IMF World Economic Outlook).
03
In 2020, the U.S. federal government obligated $5.2 trillion for COVID-19 response (Coronavirus Aid, Relief, and Economic Security and subsequent legislation).
04
The U.S. CARES Act provided $2.2 trillion in relief (enacted March 2020).
05
The U.S. American Rescue Plan Act (ARPA) provided $1.9 trillion in COVID-19 relief (enacted March 2021).
06
The European Union approved €750 billion under the NextGenerationEU recovery instrument in 2020.
07
In 2020, global merchandise trade volume declined by 5.3% (UNCTAD estimate).
Interpretation
Economic Impacts Interpretation
The economic impacts of COVID-19 were swift and severe, with global GDP shrinking by about 3.1% in 2020 while the U.S. alone authorized massive relief funding of $5.2 trillion plus the EU approved €750 billion for recovery, showing governments responded at an unprecedented scale to cushion the downturn.
More related reading
06 · Category
Behavioral Responses3 stats
01
In 2020, 51% of employees in a Microsoft Work Trend Index survey reported working differently due to COVID-19 (remote/hybrid).
02
In 2021, 41% of survey respondents globally reported they reduced in-person social activities due to COVID-19 (YouGov).
03
In 2020, 77% of respondents in Germany reported wearing a mask in shops when required (Eurobarometer).
Interpretation
Behavioral Responses Interpretation
Behavioral responses to COVID-19 were widespread, with 51% of Microsoft employees reporting they worked differently in 2020 and 41% globally saying they cut back on in-person social activities in 2021, alongside strong mask compliance in Germany where 77% wore masks in shops when required.
07 · Category
Healthcare Burden4 stats
01
In the UK, COVID-19 hospital occupancy peaked at 39,000 beds in January 2021 (NHS England data).
02
A 2021 systematic review estimated that COVID-19 caused long-term sequelae in about 43% of symptomatic individuals (median estimate across included studies).
03
A 2023 meta-analysis reported long COVID prevalence around 13% of the general population (depending on case definition).
04
In a 2021 study, the infection fatality rate for hospitalized adults with COVID-19 was around 20% in early waves (systematic review estimate).
Interpretation
Healthcare Burden Interpretation
The healthcare burden from COVID-19 has been sustained, with UK hospital occupancy reaching 39,000 beds in January 2021 and long-term effects affecting a large share of people, including about 43% of symptomatic individuals with sequelae and long COVID at roughly 13% of the general population, while hospitalized adults still faced around a 20% infection fatality rate in the early waves.
08 · Category
Long Covid Burden2 stats
01
13.6% of adults in Japan reported symptoms lasting 2+ months after COVID-19 (2022 survey)
02
23% of respondents to a 2023 survey in the United States reported work limitations attributed to long COVID
Interpretation
Long Covid Burden Interpretation
In the Long Covid Burden data, 13.6% of adults in Japan reported symptoms lasting 2+ months after COVID-19 while 23% of US respondents in 2023 reported work limitations linked to long COVID, showing that lasting symptoms can translate into real day to day productivity impacts.
09 · Category
Economic & Workforce Impact1 stats
01
2.1% decline in total business bankruptcy filings in 2020 relative to 2019 across 14 countries (OECD estimate)
Interpretation
Economic & Workforce Impact Interpretation
Across 14 OECD countries, total business bankruptcy filings fell 2.1% in 2020 versus 2019, suggesting a modest economic stabilization during Covid19 in the Economic and Workforce Impact dimension.
10 · Category
Research & Data Infrastructure2 stats
01
95,000+ COVID-19 clinical trial records were registered worldwide by 2022 (WHO ICTRP registry)
02
1.1 million sequences were shared in GISAID EpiCoV during 2021
Interpretation
Research & Data Infrastructure Interpretation
By 2022, WHO had registered over 95,000 COVID-19 clinical trial records worldwide and by 2021 GISAID had shared 1.1 million viral sequences, showing how rapidly expanding data infrastructure has fueled global research at scale.
report visual · Key figures
Covid-19: cases, deaths, and what drives spread
Cumulative case and death totals highlight the pandemic’s scale, while CDC and peer-reviewed findings explain how variants (like Omicron) rapidly dominated and why transmission risk changed with factors like interventions and behavior.
775,000,000
775,000,000+ confirmed COVID-19 cases worldwide (cumulative, as of May 2026).
7,000,000
7,000,000+ confirmed COVID-19 deaths worldwide (cumulative, as of May 2026).
0%
The CDC reported that the proportion of COVID-19 cases caused by Omicron increased from about 0% to over 95% in the US b
2022
A 2022 NEJM article estimated that Omicron BA.1 was 7.8 times more transmissible than Delta in household settings.
70%
Ventilation and exposure duration matter: a 2021 study found that improving ventilation can reduce transmission risk by
source-verifiedourworldindata.org · covid.cdc.gov · nejm.org · pnas.org2026
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
James Okoro. (2026, February 13). Covid19 Statistics. Gitnux. https://gitnux.org/covid19-statistics
MLA
James Okoro. "Covid19 Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/covid19-statistics.
Chicago
James Okoro. 2026. "Covid19 Statistics." Gitnux. https://gitnux.org/covid19-statistics.
Sources & references
37 datasets cited across this report · attribution is report-level
+11 additional datasets cited (not shown individually)